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Abstract We have investigated the binding of bepridil to
calcium-saturated cardiac troponin C in a cardiac troponin C/
troponin I complex. Nuclear magnetic resonance spectroscopy
and [15N,2H]cardiac troponin C permitted the mapping of
bepridil-induced amide proton chemical shifts. A single bepri-
dil-binding site in the regulatory domain was found with an
affinity constant of V140 WM31. In the presence of cardiac
troponin I, bepridil binding to the C domain of cardiac troponin
C was not detected. The pattern of bepridil-induced chemical
shifts is consistent with stabilization of more open regulatory
domain conformational states. A similar pattern of chemical shift
perturbations was observed for interaction of the troponin I
cardiac-specific amino-terminus with the cardiac troponin C
regulatory domain. These results suggest that both bepridil and
the cardiac-specific amino-terminus may mediate an increase in
calcium affinity by interacting with and stabilizing open
regulatory domain conformations. Chemical shift mapping
suggests a possible role for inactive calcium-binding site I in
the modulation of calcium affinity. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Cardiac muscle contraction is regulated by calcium-depen-
dent interactions between members of the troponin (Tn) com-
plex and other thin ¢lament proteins including actin and tro-
pomyosin. This complex consists of TnC, I, and T. TnC is the
Ca2-binding subunit of the troponin complex and a potential
drug target in the therapy of congestive heart failure. TnT
makes primary contact with tropomyosin while troponin I
participates in the major protein^protein interaction with re-
combinant cTnC (desMet1-Ala2, Cys35Ser) (cTnC).
Cardiac TnC and TnI interact in head to tail fashion such
that the C domain of cTnC interacts with the N domain of
cTnI [1]. The C domain of cTnC contains two high a⁄nity
Ca2/Mg2-binding sites whereas the N domain, or regulatory
domain, contains a single active low a⁄nity Ca2-speci¢c
binding site, site II. Site I in the cardiac isoform is naturally
inactive [2]. This region has been suggested to modulate con-
formational states within the regulatory domain. Structures
for the N domain of cTnC bound to cTnI(147^163) [3] and
the C domain of cTnC bound to cTnI(33^80) [4] have been
determined. Structural information has not been obtained on
the £exible linker connecting globular domains. Cardiac TnI
contains a 32 amino acid N-terminal extension that can be
phosphorylated at Ser residues 23 and 24 by cAMP-dependent
protein kinase A [5]. In the absence of phosphorylation, this
region is proposed to interact with the cTnC regulatory do-
main [6].
Many EF-hand proteins undergo a conformational change
upon Ca2 binding leading to exposure of a hydrophobic
pocket or cleft, referred to as the open/active form, which
interacts with appropriate target proteins. The increased a⁄n-
ity of Ca2 for the open form is thought to provide the driv-
ing force for exposure of the hydrophobic cleft. In the cardiac
system, activation of cTnC appears to require interactions
with both Ca2 and the cTnI regulatory region [3,7,8]. Ex-
change between open and closed N domain conformational
substates has been observed in the presence of Ca2 and cTnI
[6,9,10]. Phosphorylation of the cardiac-speci¢c amino-termi-
nus, as a consequence of L-adrenergic stimulation, disrupts
this regulatory domain interaction resulting in decreased
Ca2 a⁄nity and decreased Ca2 sensitivity of contraction
[6,11,12].
Bepridil is one member of a class of pharmacological com-
pounds capable of binding cTnC and modulating regulatory
domain Ca2 a⁄nity [13,14]. Early studies found an apparent
bepridil Ka of 10 WM31 for binding to Ca2-saturated cTnC
[14]. In the presence of bepridil, Ca2 a⁄nity at site II, the
regulatory site, increased [15,16]. This increase was observed
in both slow and fast skeletal muscle ¢bers, with the e¡ect
being greater in slow ¢bers [17]. Nuclear magnetic resonance
(NMR) studies, using Met residues as structural markers,
identi¢ed three or four bepridil-binding sites in cTnC [18].
Recently, an X-ray crystal structure of Ca2-saturated cTnC
with three bound bepridil molecules has been obtained [19].
The overall cTnC structure was compact with the two glob-
ular domains close together [19]. Two bepridil molecules are
located in the hydrophobic cavity between domains and make
contact with both domains. A single bepridil appears to sta-
bilize an open regulatory domain conformation by inserting
between helical pairs A-D and B-C, sterically preventing do-
main closing [19].
These studies prompted us to explore bepridil binding to
the cTnC/cTnI complex. Amide proton chemical shift pertur-
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bation mapping was used to monitor e¡ects of bepridil on
cTnC in [15N,2H]cTnC/cTnI(1^211). Bepridil binding induces
1H^15N amide chemical shift changes within the cTnC regu-
latory domain consistent with a shift in conformational equi-
libria toward more open states. Stabilization of a more open
conformation is the expected activity of a Ca2-sensitizing
agent. In the presence of cardiac TnI, no binding of bepridil
to the C domain of cardiac TnC was detected. Our studies
demonstrate the usefulness of this system for screening com-
pounds capable of stabilizing open/active regulatory confor-
mations.
2. Materials and methods
2.1. Proteins
[15N,2H]cTnC and cTnI(1^211) were expressed and puri¢ed as pre-
viously described [9,20]. Ca2-saturated [15N,2H]cTnC/cTnI com-
plexes were prepared at a known concentration, usually 0.4^0.6
mM, in 10% 2H2O, 20 mM Tris-d11 (pH 6.8), 500 mM KCl, 10
mM CaCl2, 5 mM dithiothreitol, 0.1 mM pefabloc and 0.1 mM leu-
peptin.
2.2. Bepridil titration
Stock solutions of bepridil (Sigma) were prepared fresh in 10% d4-
methanol, and added in aliquots to Ca2-saturated [15N,2H]cTnC/
cTnI. Sample pH was corrected to 6.8 as necessary. Binding of bepri-
dil to Ca2-saturated [15N,2H]cTnC/cTnI was monitored by following
bepridil-induced 1HN chemical shift changes. Chemical shift changes
were judged signi¢cant when they exceeded the sum of the average
plus one S.D. of all bepridil-induced 1HN shifts. Normalized average
1HN chemical shift data as a function of total bepridil were utilized to
estimate Ka for drug binding.
2.3. NMR spectroscopy
Experiments were carried out on a Varian Inova 800 MHz spec-
trometer. 1H^15N correlation experiments utilized sensitivity-enhanced
1H^15N HSQC-based pulse sequences [21]. Data collection and pro-
cessing parameters have been previously described [8].
3. Results
Our laboratory has developed an intact cTnC/cTnI model
useful for understanding structural mechanisms involved in
activation and modulation of contraction. One of the many
advantages in utilizing intact cTnC/cTnI for structural studies
is the ability to avoid or reduce non-speci¢c peptide and drug
interactions [22]. To further our structural understanding of
activation and modulation of the Ca2 signal, we have studied
the binding of a known Ca2-sensitizing agent, bepridil, to the
Ca2-saturated cTnC/cTnI complex having a molecular mass
of V40 kDa.
A 1:1 complex of Ca2-saturated [15N,2H]cTnC and cTnI
was prepared and characterized as previously described [8].
We have previously assigned both amide proton, 1HN, and
nitrogen,15NH, resonances in Ca2-saturated [15N,2H]cTnC
bound to full-length cTnI. 1H^15N HSQC spectra were used
to map bepridil binding to cTnC during titration of Ca2-
saturated cTnC/cTnI. Fig. 1 compares 1HN chemical shift
di¡erences for Ca2-saturated cTnC bound to cTnI in the
absence and presence of saturating drug. Chemical shift di¡er-
ences map primarily to defunct site I and Ca2-binding site II
(Fig. 1). No signi¢cant bepridil-induced amide chemical shift
changes were observed in the cTnC C domain demonstrating
that any potential drug-binding sites in the C domain are
blocked in the presence of cTnI (Fig. 1). This is in contrast
to crystallographic studies and solution studies on free Ca2-
saturated cTnC where at least two C domain bepridil-binding
sites were detected [18,19].
Binding site chemical shift perturbations indicate where the
magnetic environment is changing upon addition of bepridil.
While chemical shift changes often map to the binding inter-
face, changes resulting from perturbation of regulatory do-
main equilibria may also be detected. Single 1H^15N correla-
tions were observed for amide protons whose chemical shift
could be followed with increasing bepridil concentration, con-
sistent with fast exchange between conformational substates
relative to chemical shift di¡erences between free and drug-
bound forms. In addition to residues in and around sites I and
II, chemical shift perturbations were also observed for selected
residues in the A-, B-, and D-helices (Fig. 1). Broadening of
1HN resonances for cTnC residues 36^41, 50^54, 60^62, 64^
67, 74^78, and 80^86 in either the presence or absence of
saturating bepridil precluded mapping drug-induced chemical
shift perturbations within these regions (Fig. 1). Many of
these residues have been previously demonstrated to undergo
chemical exchange in several di¡erent cTnC/cTnI complexes
[8]. The observed broadening is consistent with conformation-
al exchange that persists even in the presence of bepridil.
Taken together, our data suggest that bepridil-induced 1HN
chemical shifts not only localize bepridil binding to the cTnC
N domain, but also reveal changes in regulatory domain con-
formational substates. Identi¢cation of the bepridil-binding
interface in the regulatory domain requires measurement of
distance restraints, NOEs, in appropriately isotope-labeled
cTnC/cTnI complexes. In this study, the presence of proton-
ated cTnI precluded the possibility of detecting NOE interac-
tions between bepridil and regulatory domain 1HN resonan-
ces.
Analysis of the 1HN chemical shift dependence with increas-
ing concentrations of drug was used to estimate an apparent
Fig. 1. Comparison of absolute value amide chemical shift di¡eren-
ces between Ca2-saturated [15N,2H]cTnC/cTnI and Ca2-saturated
[15N,2H]cTnC/cTnI in the presence of saturating bepridil. Chemical
shift di¡erences were measured for 1HN resonances of cTnC in a
0.5 mM Ca2-saturated [15N,2H]cTnC/cTnI complex in the absence
and presence of 2 mM bepridil. The horizontal line represents the
average chemical shift di¡erence plus one S.D. Filled circles mark
residues for which resonance assignments in one of the 1H^15N cor-
relation spectra were broadened as a consequence of chemical ex-
change or could not be con¢rmed.
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Ka of V140 WM31 for bepridil binding to the cTnC regula-
tory domain in Ca2-saturated cTnC/cTnI. This value is 10-
fold greater than the published value for bepridil binding to
free cTnC [14]. At the high protein concentration used in the
NMR titrations, care must be taken to look for and minimize
non-speci¢c, weak associations. Absence of bepridil-induced
cTnC C domain chemical shifts, even in the presence of excess
drug, suggests 1HN chemical shifts in the regulatory domain
re£ect speci¢c association. The apparent weak binding of be-
pridil to the cTnC regulatory domain in the complex may in
part explain its poor pharmacological e¡ects [14,15].
4. Discussion
We have utilized our 1HN assignments for [15N,2H]cTnC
bound to cTnI to study bepridil binding and its e¡ects on
regulatory domain conformational substates. Observed regu-
latory domain chemical shift changes map primarily to de-
funct site I and Ca2-binding site II (Fig. 1). Both the direc-
tion and magnitude of Ala-31 and Asp-73 1HN chemical shift
changes are consistent with stabilization of open regulatory
domain conformations. A similar pattern of chemical shift
perturbations has been attributed to interaction of the cTnI
cardiac-speci¢c amino-terminus with the cTnC regulatory do-
main [8,20]. Observed chemical shift changes are similar to
those detected upon opening of the N domain in response
to cTnI(129^166) binding [23].
The apparent bepridil-binding constant is weaker than that
determined for free cTnC [14,15,18]. Several possible expla-
nations could account for the apparent di¡erence in binding
a⁄nities. Analysis of the crystal structure of bepridil bound to
cTnC shows an overall collapsed structure. Collapse of cTnC
results in all three bound bepridil molecules having interac-
tions with both cTnC domains [19]. In the presence of cTnI,
cTnC is more elongated and therefore it is less likely that both
cTnC domains contribute to the binding a⁄nity of bepridil
[8,24,25]. Our studies show that in the presence of cTnI, two
apparent bepridil-binding sites within the C domain are
blocked (Fig. 1). This observation is consistent with available
structures suggesting that C domain drug-binding sites over-
lap with the cTnI N domain-binding site [4,19]. Recently, it
has been demonstrated that both bepridil and a cTnI regula-
tory peptide can bind to the isolated N domain of cTnC [26].
This observation would suggest that decreased bepridil a⁄nity
for cTnC in the cTnC/cTnI complex does not result from
competitive binding interactions. Our recent comparison of
regulatory conformational substates in cTnC/cTnI(1^80)/
cTnI(129^166) and cTnC/cTnI(1^167) suggests that covalent
attachment of the cTnI N domain to the cTnI regulatory
region, via residues 81^128, modulates interactions between
the cTnI regulatory region and the cTnC N domain [23],
leaving open the possibility that cTnI may alter bepridil bind-
ing in the intact system.
We have previously demonstrated that interaction of the
cTnI cardiac-speci¢c amino-terminus with cTnC alters regu-
latory domain conformational substates, presumably toward
more open/active conformations [9,20,23]. Phosphorylation of
Ser-23 and Ser-24 in the cardiac-speci¢c amino-terminus is
thought to result in the loss of these cTnC regulatory domain
interactions. Regulatory domain chemical shift changes ob-
served upon drug binding and upon interaction with the
cTnI cardiac-speci¢c amino-terminus [20] suggest that both
Fig. 2. The conformation of Ca2-saturated cTnC when bound to cTnI is shown with regions colored to indicate 1HN chemical shift changes
upon binding bepridil (A) and the cTnI cardiac-speci¢c amino-terminus (B). The conformation of Ca2-saturated cTnC bound to cTnI was de-
termined using long-range distance and orientation restraints (Abusamhadneh, unpublished). A: Calcium-saturated cTnC residues whose 1HN
chemical shift changes in the presence of bepridil (Fig. 1) are shown in red. B: Cardiac TnC residues whose 1HN chemical shifts are perturbed
by binding the cTnI cardiac-speci¢c amino-terminus are shown in yellow. Residues whose 1HN chemical shifts exhibit signi¢cant chemical shift
perturbations were obtained by comparing the absolute values of the 1HN chemical shift di¡erences between cTnC/cTnI(1^80) and cTnC/phos-
phorylated cTnI(1^80) [22]. Residues experiencing signi¢cant perturbations in the presence of the cTnI cardiac-speci¢c amino-terminus include
21, 22, 23, 25, 29, 32, 33, 34, 35, 42, 43, 55, 57, 67, 68, 69, 71, 72, 73, 81, 84, and 90.
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induce similar cTnC regulatory domain conformational
changes (Fig. 2). Bepridil binding to the regulatory domain
has been shown to extend the N-terminus of helix B with
formation of a side chain interaction, between Glu-40 and
Ser-37 [19]. These structural changes have been suggested to
stabilize defunct site I and facilitate regulatory domain open-
ing [19]. It is interesting to speculate that the cTnI cardiac-
speci¢c amino-terminus also stabilizes site I and thereby in-
creases the population of open/active conformations. Thus,
the inability of site I to bind Ca2 produces a conformation-
ally active region capable of modulating the overall conforma-
tional entropy and therefore populations of apo/closed and
Ca2-cTnI/open states. Consistent with this proposal, binding
of the cardiac-speci¢c amino-terminus and bepridil are both
known to increase the apparent Ca2 a⁄nity for Ca2-binding
site II. Thus, our studies provide evidence for a conformation-
ally active region within the cTnC regulatory domain that
may be targeted for development of Ca2-sensitizing com-
pounds capable of increasing Ca2 a⁄nity in cardiac tropo-
nin.
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